Taysha Gene Therapies, Inc. TSHA
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -13.07% | -32.27% | 3.42% | 17.28% | -36.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -13.07% | -32.27% | 3.42% | 17.28% | -36.36% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -13.07% | -32.27% | 3.42% | 17.28% | -36.36% |
| SG&A Expenses | 38.21% | 24.44% | 17.85% | 16.98% | 20.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.70% | 66.64% | 53.99% | 26.66% | 17.36% |
| Operating Income | -61.01% | -75.62% | -58.36% | -27.56% | -23.81% |
| Income Before Tax | -56.14% | -61.38% | -49.69% | -22.06% | -338.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -56.14% | -61.38% | -49.69% | -22.06% | -338.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.14% | -61.38% | -49.69% | -22.06% | -338.82% |
| EBIT | -61.01% | -75.62% | -58.36% | -27.56% | -23.81% |
| EBITDA | -61.71% | -76.60% | -59.26% | -28.08% | -24.39% |
| EPS Basic | -25.13% | -23.02% | -12.32% | 5.18% | -432.32% |
| Normalized Basic EPS | -29.84% | -35.66% | -20.55% | 0.50% | -2,532.00% |
| EPS Diluted | -25.13% | -23.02% | -12.32% | 5.18% | -432.32% |
| Normalized Diluted EPS | -29.84% | -35.66% | -20.55% | 0.50% | -2,532.00% |
| Average Basic Shares Outstanding | 26.08% | 31.07% | 32.45% | 27.76% | 26.15% |
| Average Diluted Shares Outstanding | 26.08% | 31.07% | 32.45% | 27.76% | 26.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |